This issue was resolved through T-Dxd (DS-8201) that proved to overrate T-DM1 in HER2+ as well as in HER2 low BC (HER2 IHC 1+ or 2+ without HER2 gene amplification according to results of DESTINY-Breast04 trial [57, 58]. This evidence concerns the gene ERBB2 and breast cancer.